1 A disturbance in body water homeostasis is a common feature in advanced @entity82 . This disturbance is always associated with the existence of @entity843 and is characterized by an inability to adjust the amount of water excreted in the urine to the amount of water ingested. @entity1951 (AVP) is of major importance in the pathogenesis of water retention and @entity2753 in @entity82 . 2 The current study assessed the renal, hormonal and hemodynamic effects induced by 10-day chronic oral administration of @entity68038 (0.5 mg kg(-1) daily), a new nonpeptide V(2)-AVP antagonist, in @entity35 with @entity14605 -induced @entity82 , @entity843 and severe water retention. Urine volume (UV), urine osmolality and @entity1372 and @entity972 excretion were measured daily. At the end of the study, systemic hemodynamic parameters were also assessed. 3 Long-term administration of @entity68038 has an aquaretic effect in @entity35 with @entity82 , @entity843 , water retention and @entity9680 . It increases UV (ANOVA: F=7.32, P<0.0001) and reduces urine osmolality (ANOVA: F=12.69, P<0.0001) throughout the entire period of treatment, thereby leading to a greater renal ability to excrete a water load at the end of the 10-day treatment period (the percentage of water load excreted improved from 30+/-8 to 92+/-21%, P<0.025). 4 The nonpeptide AVP V(2)-receptor antagonist @entity68038 also increased @entity1372 excretion without affecting @entity1011 clearance and blood pressure. 5 These data suggest that @entity68038 could be therapeutically useful in the treatment of water retention in @entity1 @entity82 .

Sustained aquaretic effect of the V2-AVP receptor antagonist, @entity68038 , in cirrhotic XXXX with @entity843 and water retention.

@entity1 :: ('9606', 'Species') :: ['human'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity14605 :: ('CHEBI:27385', 'Chemical') :: ['CCl(4)'] @entity843 :: ('MESH:D001201', 'Disease') :: ['ascites'] @entity68038 :: ('MESH:C507921', 'Chemical') :: ['RWJ-351647'] @entity1951 :: ('MESH:D014667', 'Chemical') :: ['Vasopressin'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['sodium'] @entity9680 :: ('MESH:D052456', 'Disease') :: ['hypo-osmolality'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity2753 :: ('MESH:D007010', 'Disease') :: ['hyponatremia']
@entity35 :: (10116,Species) :: ['rats']
